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Introduction
Chronic myeloid leukemia is a hemopoietic stem
cell clonal disorder characterized by granulocytic
leucocytosis, basophilia, anemia, thrombocytosis and
splenomegaly. Chronic myeloid leukemia is
characteristically a tri-phasic disease in which the chronic
phase usually lasts for three to six years followed by
transformation to accelerated phase and blast crisis.1
The hallmark of this malignancy is the Philadelphia
chromosome positivity, a reciprocal translocation between
the long arms of chromosomes 9 and 22. bcr from
chromosome 22 binds to abl of chromosome 9 which results
in a fusion gene, the bcr-abl gene that directs the synthesis
of a novel 210 KD oncoprotein, the bcr-abl protein. It
constitutes an active protein tyrosine kinase with an
important role in the cell growth.2,3
Among the available treatment options, the allogenic
bone marrow transplantation is potentially curable but less
than 30% of patients have an HLA matched sibling donor.
Interferon can induce a complete cytogenetic response in 5
to 20 percent of patients, however with substantial serious
side effects. Hydroxyurea and other cytotoxics can produce
remarkable hematological responses but cytogenetic
response is rare.4 Recently Imatinib mesylate has been
introduced which is a potent Inhibitor of the bcr-abl tyrosine
kinase protein. Imatinib mesylate has already showed
remarkable hematological and cytogenetic responses in
patients with all phases of chronic myeloid leukemia in
phase trials.5 In this study, we share our experience of
Imatinib mesylate in eleven patients.
Patients and Methods
The study was conducted at the Aga Khan University
Hospital on patients with a diagnosis of chronic myeloid
leukemia treated with Imatinib mesylate from May 2001 to
October 2002. Inclusion criteria were: age more than
eighteen years. Chronic myeloid leukemia was diagnosed
on chromosomal studies revealing Philadelphia
chromosome on bone marrow or bcr-abl translocation by
polymerase chain reaction (PCR) analysis. Chronic phase
was defined as peripheral blast count of less than 5% and
the presence of less than 10% blast cells or less than 20%
blasts plus promyelocytes in the marrow. Accelerated phase
was defined as peripheral blasts more than 5% and the
presence of 10% blast cells or 20% blasts plus
promyelocytes in the marrow. Blast phase was defined as
blast cells more than 30% in the bone marrow. Chronic
phase interferon resistant was defined as who failed to
achieve any cytogenetic response on bone marrow in six
months time.
Before the start of Imatinib mesylate, complete
blood count, liver function tests, serum creatinine and
electrolytes were done. While on Imatinib mesylate
complete blood counts were done once a week, while the
other investigations were performed in four weeks time.
Treatment was held if absolute neutrophil count dropped
below 500/cumm and platelet count less than 10,000/cumm
in patients with blast crisis and accelerated phase. In
patients with chronic phase disease, the dose of the drug
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Abstract
Objective: To evaluate the response of Imatinib mesylate in patients with myeloid leukemia in chronic ,
accelerated and blast phase.
Patients and Methods: Eleven patients with established diagnosis of chronic myeloid leukemia were treated
with Imatinib mesylate. Adverse events were documented with regular follow ups. Hematological and cytogenetic
responses were assessed according to established criteria. Patients with zero percent Philadelphia positive
metaphases were labeled as complete cytogenetic response while patients with 1% to 35% Philadelphia positive
metaphases were termed as partial responders.
Results: Of 11 cases there were 7 males and 4 females with a mean age of 39.5 years and median age 51 years
(range 21-69). Male to female ratio was 7:4. Median follow-up was 34 weeks (range 8-78). Four patients were
in blast crisis, 1 in accelerated phase and remaining six patients were in chronic phase. All patients achieved
hematological response. Cytogenetic response was present in six patients, 3 were responders and the remaining
were non responders. Two patients achieved complete cytogenetic response and one patient had partial
cytogenetic response. Both patients with complete cytogenetic response relapsed in twelve weeks time.
Conclusion: Imatinib mesylate is a drug with curative potential and can be used as a first   
line drug in the management of CML, however at present the cure rate is unknown (JPMA 54:17;2004).
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was titrated with absolute neutrophil count of 1000/cumm
and platelet count of 50,000/cumm.
Patients in chronic phase were treated with oral
Imatinib mesylate at a dose of 400mg daily for a period of
at least three months. Similarly patients of accelerated phase
and blast crisis were started on Imatinib mesylate 600mg
daily for three months. Treatment with Imatinib mesylate
was held in those patients who achieved complete
cytogenetic response on bone marrow and negative PCR
examination for bcr-abl on  blood. Complete blood counts
and bcr-abl translocation in whole blood was performed
monthly in patients who achieved complete cytogenetic
response and treatment was restarted when the bcr-abl
translocation reappeared in the blood.
Hematological response was evaluated after four
weeks of Imatinib mesylate therapy.
Chronic phase patients: white blood cells less than
10,000/cumm, platelets less than 450,000/cumm,
myelocytes plus metamyelocytes less than 5% in the blood,
no blasts and promyelocytes in the blood and basophils less
than 20%.
Accelerated phase and blast crisis 
No evidence of blasts on peripheral film
examination, absolute neutrophil count more than
1,000/cumm and platelet counts more than 20,000/cumm or
return to chronic phase as described above.
Cytogenetic response was assessed at three months
interval while evaluating cells for presence of Philadelphia
chromosomes in bone marrow. At least fifteen cells were
counted. A major response combines both complete and
partial responses and that are defined as:
Complete: Zero percent Philadelphia positive metaphases in
bone marrow.
Partial: 1% to 35% Philadelphia positive metaphases in
bone marrow.
bcr-abl translocation in whole blood was examined who
achieved complete cytogenetic response on bone marrow
examination.
Results
Eleven patients received Imatinib mesylate. At the
start of the therapy, four patients were in blast crisis and one
in accelerated phase. Among the remaining six patients, two
were interferon resistant in chronic phase while the other
four were in denovo chronic phase. Mean age of the patients
was 39.5years, median age 51years (range 21-69). Male to
female ratio was 7:4. Median follow up was 34-weeks
(range 8-78 weeks). The other characteristics of patients are
given in Tables 1 and 2.
All patients achieved hematological responses
Table 1. Characteristics of patients in blast and accelerated phase of CML.
No. Age Gender Date  of  Diagnosis Disease phase at Dosage of Weeks on 
start of Imatinib Imatinib Imatinib
1 69 F June 1994 Blast 600 78
2 51 M September 1998 Blast 600 08
3 51 F June 1997 Blast 600 11
4 35 M November 2001 Blast 600 21
5 55 M May 2000 Accelerated 600 57
Table 2. Characteristics of patients in chronic phase of CML.
No. Age Gender Date  of  Diagnosis Disease phase Dosage Weeks on Glivec 
1 34 M September 1994 IFN resistant Chronic 400 68
2 43 M February 2000 IFN resistant Chronic 400 40
3 52 M December 2000 Chronic phase 400 32
4 37 F February 1999 Chronic phase 400 50
5 21 F May 2000 Chronic phase 400 10
6 37 M December 2001 Chronic phase 400 12
J Pak Med Assoc18
(Figures 1 and 2). Out of four patients of blast crisis, two
went into chronic phase, the other two showed
disappearance of blast cells, however, one of them expired
after 8-weeks of therapy secondary to sepsis while the other
patient revealed an initial response to drug but died of
progressive disease after eleven weeks. Only one patient
was in accelerated phase and he achieved complete
hematological response in 8 weeks. 
All six patients in chronic phase achieved complete
hematological responses, but one of them developed blast
crisis after 32-weeks of Imatinib therapy and died due to
progressive disease.
Cytogenetic responses were evaluable in six patients
(Table 3). Three were responders and the remaining three
were non-responders. Out of three responders, two attained
complete response and one showed partial response. All of
them were in chronic phase. In the two patients who
achieved complete cytogenetic response, bcr-abl
translocation was not found in the blood. 
Discussion
Chronic myeloid leukemia is invariably a fatal
disease and only a small number of patients achieve
cytogenetic response to interferon and few others are
fortunate enough to receive HLA matched bone marrow
transplant.6 Imatinib mesylate which was marketed in year
2001 is probably the first drug which acts at the molecular
level and is effective enough to produce remarkable results
in an indolent malignancy. In phase III trials the most
notable thing is the cytogenetic response of 49% in patients
with chronic phase interferon resistant group.5 Cytogenetic
response is not only noted in chronic phase interferon
resistant group but a substantial number of patients in
accelerated phase and blast crisis attain cytogenetic
remission which is not reported with any other form of
therapy.
In a recently published study those patients who
were in chronic phase interferon resistant group, the
hematological and cytogenetic responses were 95% and
60% respectively after a follow-up of 18 months.7 In
another study the cytogenetic response was assessed after a
follow-up of 14 months and approximately 1/3 of the
patients were resistant, 1/3 were partial responders and 1/3
were complete responders.8
In this study six patients were in chronic phase, out
of which two were interferon resistant, one expired because
of blast transformation even though he was started on
Imatinib mesylate soon after the diagnosis. In the remaining
five patients, three showed cytogenetic response however
one patient relapsed soon after cessation of therapy.
Table 3. Hematological and cytogenetic response.
Hematological response
Response evaluable 11 patients
Return to chronic phase and 5  patients (4 blast phase, 
clearance of blasts 1 accelerated phase)
Normalization of counts 6  patients (chronic phase)
Cytogenetic response
Response evaluable 6 patients
Responders 3 patients
Non responders 3 patients
Complete response ( 0 % Ph 2 patients 
chromosome positive metaphases)
Partial response ( 1-35% Ph 1 patient
Chromosome positive metaphases)
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Four patients were in blast crisis, two patients
returned to chronic phase with therapy while other two
expired because of progressive disease and sepsis after an
initial hematological response. Only one patient was in
accelerated phase who achieved an excellent hematological
response.
The drug was well tolerated and only minimal
adverse reactions were noted including nausea, vomiting,
periorbital edema and fluid retention.
In summary, our study is small but patients
belonging to all phases of the disease were included.
Hematological response was excellent. The most notable
finding is the clearance of blasts and return to chronic phase
in patients with blast crisis which is also noted in another
study.9 One of our patient is in chronic phase with a follow-
up of more than one and a half year with continuing
Imatinib therapy. However there was mixed cytogenetic
response. The two patients who achieved complete
cytogenetic response relapsed in twelve weeks time. This
indicates that the therapy with Imatinib mesylate may need
to be continued indefinitely for maintenance of
hematological and cytogenetic responses. Despite the
promising results, the resistance to Imatinib mesylate is a
major concern.10
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Abstract
Objective: To determine the effect of indwelling urinary catheter on frequency of intraprostatic tissue infection
and posto-perative morbidity in patients with benign prostatic hyperplasia undergoing transurethral resection of
prostate (TURP).
Methods: Frequency of intraprostatic tissue and urinary infection, prevalent organisms, histopathology of
prostatic tissue, post-operative morbidity were analyzed for 25 consecutive patients' of clinically diagnosed
benign prostatic hyperplasia who underwent TURP in catheterized and non-catheterized groups.
Results: Patients mean age was 62.2+7.9 years. In non-catheterized group nocturia and frequency were the most
common symptoms. Ninety two percent and 28% patients acquired intraprostatic tissue infection in catheterized
and non-catheterized group respectively, while 80% of catheterized patients and 24% of the non-catheterized
patients had bacteriuria. Catheterized patients had E. coli as prevalent organism both in intaprostatic tissue and
urine (34.8% and 40% respectively). E. coli Serratia and enterobacter were equally prevalent in intraprostatic
tissue of non-catheterized patients. Enterobacter was the prevalent organism in urine (50%) of these patients.
There was no significant difference in the presence of non-specific inflammatory cells in the two groups.
Catheterized group showed significantly high frequency of fever >38.5oC and hematuria for more than 24 hours.
Conclusion: Catheterization significantly increases the frequency of intraprostatic tissue infection as well as
morbidity of TURP (JPMA 54:20;2004).
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